Low Dose Apixaban As Secondary Prophylaxis for Venous Thromboembolism in Cancer Patients, 30 Months Follow-up

Trine-Lise Larsen,Herish Garresori,Jorunn Brekke,Tone Ronnaug Enden,Hege Froen,Eva-Marie Jacobsen,Petter Quist-Paulsen,Alina Carmen Porojnicu,Anne Hansen Ree,Dag Torfoss,Elin Osvik Velle,Hilde Skuterud Wik,Waleed Ghanima,Per Morten Sandset, Anders E. A. Dahm

BLOOD（2021）

引用 20|浏览12

暂无评分

摘要

Background: Apixaban is a treatment option for venous thromboembolism (VTE) in cancer patients. There are no data on the effect of low dose apixaban after 6 months treatment. We wanted to assess the efficacy and safety of apixaban 2.5 mg twice daily as prophylaxis for recurrent VTE after 6 months initial treatment with full-dose apixaban.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要